ORTINGLOBE16.30

ORTIN GLOBAL LIMITED

· Pharma & Health
AnnualQuarterly₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹13.3 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations0.30.10.10.20.10.00.00.00.00.00.00.0
Other Income0.00.00.20.0-0.00.00.00.00.00.00.30.0
Total Income0.30.10.30.20.10.00.10.10.00.00.30.0
Expenses
+ Cost of Materials Consumed-0.11.20.10.10.00.00.00.00.00.00.00.0
+ Purchases of Stock-in-Trade0.00.00.0-0.00.10.00.00.00.00.00.00.0
+ Changes in Inventories0.51.30.10.00.00.0-0.00.00.00.00.00.0
+ Employee Benefit Expense0.20.10.10.00.00.00.00.00.00.10.00.0
+ Finance Costs0.20.10.10.00.0-0.00.00.00.0-0.00.00.0
+ Depreciation & Amortisation0.10.10.00.00.00.00.00.00.00.00.00.0
+ Other Expenses0.60.23.10.20.40.10.20.20.5-0.00.30.3
Total Expenses1.42.93.50.30.50.20.20.20.50.10.30.4
EBITDA-0.9-2.6-3.2-0.1-0.4-0.1-0.2-0.2-0.5-0.0-0.3-0.3
EBIT-1.0-2.7-3.3-0.1-0.5-0.1-0.2-0.2-0.5-0.0-0.3-0.3
Profit
PBT before Exceptional Items-1.1-2.8-3.2-0.1-0.5-0.1-0.2-0.2-0.5-0.0-0.0-0.3
+ Exceptional Items0.0-0.00.00.00.00.00.00.00.00.00.00.0
Pretax Income-1.1-2.8-3.2-0.1-0.5-0.1-0.2-0.2-0.5-0.0-0.0-0.3
+ Current Tax0.00.01.30.00.00.00.00.00.00.00.00.0
+ Deferred Tax0.0-0.0-0.30.0-0.00.00.00.0-0.00.00.00.0
Tax Expense0.0-0.01.00.0-0.00.00.00.0-0.00.00.00.0
Net Income-1.1-2.8-4.1-0.1-0.5-0.1-0.2-0.2-0.5-0.1-0.0-0.3
+ Net Income — Continuing Ops-1.1-2.8-4.1-0.1-0.5-0.1-0.2-0.2-0.5-0.1-0.0-0.3
Total Comprehensive Income-1.1-2.8-4.1-0.1-0.5-0.1-0.2-0.2-0.5-0.1-0.0-0.3
Per Share
Basic EPS-1.38-3.43-5.10-0.13-0.58-0.13-0.20-0.22-0.62-0.07-0.01-0.42
Diluted EPS-1.38-3.43-5.100.00-0.58-0.13-0.20-0.22-0.62-0.07-0.01-0.42
Per Share — as-filed variants
Basic EPS — Continuing Operations-1.38-3.43-5.10-0.13-0.58-0.13-0.20-0.22-0.62-0.07-0.01-0.42
Diluted EPS — Continuing Operations-1.38-3.43-5.100.00-0.58-0.13-0.20-0.22-0.62-0.07-0.01-0.42
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period0.10.10.4
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit-0.1-2.3-0.00.1-0.00.00.0-0.00.0-0.0-0.00.0
Gross Margin %-49.33-1,706.32-11.1249.09-23.545.0780.35-17.0998.57-17.07-2.6210.34
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-1.1-2.8-3.2-0.1-0.5-0.1-0.2-0.2-0.5-0.0-0.0-0.3
− Exceptional Items (reconciliation)0.0-0.00.00.00.00.00.00.00.00.00.00.0
Net Income Adj (tax-effected)-1.1-2.8-4.1-0.1-0.5-0.1-0.2-0.2-0.5-0.1-0.0-0.3
EPS Adj-1.38-3.43-5.10-0.13-0.58-0.15-0.20-0.22-0.62-0.07-0.01-0.42
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital8.18.18.18.18.18.18.18.18.18.18.18.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.